Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 10, 108-112, February 1, 1950]
© 1950 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geisse, N. C.
Right arrow Articles by Kirschbaum, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Geisse, N. C.
Right arrow Articles by Kirschbaum, A.

Transplanted Mouse Leukemia as a Test Object for the Evaluation of Chemotherapeutic Agents*

Nancy C. Geisse, B.S.{dagger} and Arthur Kirschbaum, Ph.D., M.D.

(From the Department of Anatomy, University of Minnesota Medical School)

Potassium arsenite may actually inhibit and urethane may delay the development of certain lines of transplanted mouse myeloid leukemia, if treatment is begun within a few days after transfer. Increase in survival time, and even complete inhibition, may be obtained by limiting treatment to the first few days after inoculation of leukemic cells. Limited or no protection is provided against transplanted leukemia when these drugs are given after the host is leukemic. It would appear that these findings apply to other agents, such as the folic acid antagonists (18). Other arsenicals and chemicals closely related to urethane may exhibit no "anti-leukemic effect" when given in maximum, tolerable daily doses under the most favorable circumstances, that is, during the "pre-proliferative period" within a few days after transfer, indicating some specificity of drug action. Compounds effective in increasing survival time include those which have been used clinically. It does not follow, however, that materials effective under experimental conditions will provide palliation clinically.

* This investigation has been aided by grants from the National Cancer Institute, The Jane Coffin Childs Memorial Fund for Medical Research, The American Cancer Society, The Donner Foundation, and the Cancer Fund of the Graduate School of the University of Minnesota.

{dagger} Submitted in partial fulfilment of the requirements for the degree of Master of Science at the University of Minnesota.

Received 10/ 5/49.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1950 by the American Association for Cancer Research.